Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03793608
- Locations
- 🇨🇦
Regeneron Investigational Site, Montreal, Quebec, Canada
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT03767738
- Locations
- 🇺🇸
Regeneron Study Site, The Woodlands, Texas, United States
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 387
- Registration Number
- NCT03761108
- Locations
- 🇺🇸
University of Miami Hospital/Sylvester Comprehensive, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT03746704
- Locations
- 🇺🇸
Regeneron Study Site, New York, New York, United States
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT03738423
- Locations
- 🇬🇧
Regeneron Study Site, Sheffield, United Kingdom
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT03736967
- Locations
- 🇪🇸
Regeneron Research Site, Santiago de Compostela, Spain
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT03710941
Long Term Safety Study of PRALUENT
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1389
- Registration Number
- NCT03694197
- Locations
- 🇺🇦
Regeneron Research Site, Vinnytsya, Ukraine
🇷🇺Regeneron Research Site 2, Yaroslavl, Russian Federation
🇺🇦Regeneron Research Site #2, Kyiv, Ukraine
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT03691974
- Locations
- 🇬🇧
Regulatory Study Site, London, United Kingdom
🇬🇧Regeneron Study Site, Waterloo, United Kingdom
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT03690869
- Locations
- 🇺🇸
Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States